Reuters: Hot Stocks: Pfizer to continue developing Pain Therapeutics' painkiller

Reuters: Hot Stocks Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Manage your social media Best social media tool for image publishing to Facebook and Twitter. Look amazing and delight your followers. Get 40% off when you sign up today. From our sponsors

Pfizer to continue developing Pain Therapeutics' painkiller Oct 22nd 2013, 12:52 Tue Oct 22, 2013 8:52am EDT Oct 22 (Reuters) - Pfizer Inc said it would continue developing the abuse-resistant painkiller made by its partner Pain Therapeutics Inc and would conduct new clinical trials to address questions raised by the U.S. regulator regarding the drug. Pain Therapeutics shares jumped 22 percent in premarket trading. The drug, Remoxy, has been rejected twice by the U.S. Food and Drug Administration due to concerns about its manufacturing process and chemical composition. Remoxy was developed using the abuse-resistant technology of Durect Corp, whose shares rose 7 percent before the bell. The FDA has asked Pfizer for two studies - one to show that Remoxy was the bioequivalent of its original formulation, and another to investigate the potential for abuse of the modified version of the drug. (Reporting by Esha Dey in Bangalore; Editing by Kirti Pandey)

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions